BAY 41-2272 Treatment Improves Acetylcholine-Induced Aortic Relaxation in L-NAME Hypertensive Rats

Abstract

Hypertension, an emerging problem of recent era, and many pathophysiological factors are participating to produce the disease. Nitric oxide (NO) is an important constituent to ameliorate hypertensive condition. Inhibition of endogenous NO synthase by L-N^G-Nitroarginine methyl ester (L-NAME) was responsible for generating hypertension in rats. BAY 41-2272 (5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-pyrimidin-4-ylamine), a soluble guanylyl cyclase activator, restricts rise of blood pressure and shows cardioprotective activity. The aim of the present study was to analyze effect of short-term BAY 41-2272 treatment on blood pressure and vascular function.

Male Wistar rats were randomly divided into three groups such as control (group-A), hypertensive (group-B), and BAY 41-2272–treated hypertensive (group-C) rats. Normal saline was administered intramuscularly to control rats for last 3 days (days 40, 41, and 42) of total 42 days treatment, whereas rats of group-B and group-C were treated with L-NAME hydrochloride in drinking water at 50 mg/kg body weight daily for 42 days. Also, normal saline and BAY 41-2272 were administered for last 3 days at two different dosages at 1 and 3 mg/kg body weight/day intramuscularly to group-B and group-C rats, respectively.

Administration of BAY 41-2272 for 3 days was not sufficient enough to decrease mean arterial pressure of hypertensive rats significantly. BAY at both the treatment dosages significantly ameliorate acetylcholine-induced maximal aortic relaxation compared with BAY-untreated hypertensive rats.

Findings of the present study indicate that even shorter period of BAY 41-2272 treatment (3 days) improves vascular relaxation.

Keywords

hypertension - L-NAME - mean arterial pressure - BAY 41-2272 - thoracic aorta - improves acetylcholine relaxation - Wistar rats

• References

• 1 Psaty BM, Furberg CD, Kuller LH , et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med 2001; 161 (9) 1183-1192
• 2 Aronow WS, Fleg JL, Pepine CJ , et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol 2011; 57 (20) 2037-2114
• 3 Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med 2003; 139 (9) 761-776
• 4 Rand MJ, Li CG. Nitric oxide as a neurotransmitter in peripheral nerves: nature of transmitter and mechanism of transmission. Annu Rev Physiol 1995; 57: 659-682
• 5 Mayer B, Werner ER. In search of a function for tetrahydrobiopterin in the biosynthesis of nitric oxide. Naunyn-Schmiedeberg's Arch Pharmacol 1995; 351: 453-463
• 6 Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 1992; 20 (3) 298-303
• 7 Moore PK, Oluyomi AO, Babbedge RC, Wallace P, Hart SL. L-NG-nitro arginine methyl ester exhibits antinociceptive activity in the mouse. Br J Pharmacol 1991; 102 (1) 198-202
• 8 Joshi CN, Martin DN, Fox JC, Mendelev NN, Brown TA, Tulis DA. The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways. J Pharmacol Exp Ther 2011; 339 (2) 394-402
• 9 Bice JS, Keim Y, Stasch JP, Baxter GF. NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size. Cardiovasc Res 2014; 101 (2) 220-228
• 10 Teixeira CE, Priviero FB, Todd Jr J, Webb RC. Vasorelaxing effect of BAY 41-2272 in rat basilar artery: involvement of cGMP-dependent and independent mechanisms. Hypertension 2006; 47 (3) 596-602
• 11 Prawez S, Ahanger AA, Kandasamy K , et al. Soluble guanylylcyclase activator Bay 41–2272 improves vascular activity of thoracic aorta isolated from DOCA hypertensive male wistar rats. WJPR 2014; 3 (7) 1149-1164
• 12 Zanfolin M, Faro R, Araujo EG, Guaraldo AM, Antunes E, De Nucci G. Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. J Cardiovasc Pharmacol 2006; 47 (3) 391-395
• 13 Claudino MA, da Silva FH, Mónica FZT, Rojas-Moscoso JA, De Nucci G, Antunes E. Long-term oral treatment with BAY 41-2272 ameliorates impaired corpus cavernosum relaxations in a nitric oxide-deficient rat model. BJU Int 2011; 108 (1) 116-122
• 14 Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992; 90 (1) 278-281
• 15 Deruelle P, Balasubramaniam V, Kunig AM, Seedorf GJ, Markham NE, Abman SH. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biol Neonate 2006; 90 (2) 135-144
• 16 Kandasamy K, Prawez S, Choudhury S , et al. Atorvastatin prevents vascular hyporeactivity to norepinephrine in sepsis: role of nitric oxide and α₁-adrenoceptor mRNA expression. Shock 2011; 36 (1) 76-82
• 17 Snedecor GW, Cochran WG. Statistical Methods. 8th ed. Ames, Iowa: The Iowa State University Press; 1989
• 18 Ooshima A, Fuller G, Cardinale G, Spector S, Udenfriend S. Collagen biosynthesis in blood vessels of brain and other tissues of the hypertensive rat. Science 1975; 190 (4217) 898-900
• 19 Ooshima A, Fuller GC, Cardinale GJ, Spector S, Udenfriend S. Increased collagen synthesis in blood vessels of hypertensive rats and its reversal by antihypertensive agents. Proc Natl Acad Sci U S A 1974; 71 (8) 3019-3023
• 20 Hüsken BC, Hendriks MG, Pfaffendorf M, Van Zwieten PA. Effects of aging and hypertension on the reactivity of isolated conduit and resistance vessels. Microvasc Res 1994; 48 (3) 303-315
• 21 Küng CF, Lüscher TF. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension 1995; 25 (2) 194-200
• 22 Raij L, Baylis C. Glomerular actions of nitric oxide. Kidney Int 1995; 48 (1) 20-32
• 23 Topouzis S, Schott C, Stoclet JC. Participation of endothelium-derived relaxing factor and role of cyclic GMP in inhibitory effects of endothelium on contractile responses elicited by alpha-adrenoceptor agonists in rat aorta. J Cardiovasc Pharmacol 1991; 18 (5) 670-678
• 24 Tabernero A, Giraldo J, Vila E. Effect of NG-nitro-L-arginine methylester (L-NAME) on functional and biochemical α 1-adrenoceptor-mediated responses in rat blood vessels. Br J Pharmacol 1996; 117 (4) 757-763
• 25 López RM, Ortíz CS, Ruíz A, Vélez JM, Castillo C, Castillo EF. Impairment of smooth muscle function of rat thoracic aorta in an endothelium-independent manner by long-term administration of N(G)-nitro-L-arginine methyl ester. Fundam Clin Pharmacol 2004; 18 (6) 669-677
• 26 Prawez S, Ahanger AA, Singh TU , et al. Chronic administration of phytoestrogen “daidzein” to ameliorate mean arterial pressure and vascular function in N-G-nitro-Larginine methyl ester hypertensive rats. Veterinarski Arhiv 2015; 85 (4) 451-464
• 27 Qu C, Leung SWS, Vanhoutte PM, Man RY. Chronic inhibition of nitric-oxide synthase potentiates endothelium-dependent contractions in the rat aorta by augmenting the expression of cyclooxygenase-2. J Pharmacol Exp Ther 2010; 334 (2) 373-380
• 28 Priviero FBM, Baracat JS, Teixeira CE, Claudino MA, De Nucci G, Antunes E. Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator. Clin Exp Pharmacol Physiol 2005; 32 (9) 728-734
• 29 Priviero FBM, Zemse SM, Teixeira CE, Webb RC. Oxidative stress impairs vasorelaxation induced by the soluble guanylyl cyclase activator BAY 41-2272 in spontaneously hypertensive rats. Am J Hypertens 2009; 22 (5) 493-499
• 30 Moncada S, Rees DD, Schulz R, Palmer RM. Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci U S A 1991; 88 (6) 2166-2170
• 31 Gupta PK, Subramani J, Singh TU , et al. Role of protein kinase G in nitric oxide deficiency-induced supersensitivity to nitrovasodilator in rat pulmonary artery. J Cardiovasc Pharmacol 2008; 51 (5) 450-456
• 32 Wolinsky H. Effects of hypertension and its reversal on the thoracic aorta of male and female rats. Morphological and chemical studies. Circ Res 1971; 28 (6) 622-637
• 33 O'Rourke M. Arterial stiffness, systolic blood pressure, and logical treatment of arterial hypertension. Hypertension 1990; 15 (4) 339-347
• 34 Hashimoto J, Ito S. Aortic stiffness determines diastolic blood flow reversal in the descending thoracic aorta: potential implication for retrograde embolic stroke in hypertension. Hypertension 2013; 62 (3) 542-549
• 35 Sim MK, Singh M. Decreased responsiveness of the aortae of hypertensive rats to acetylcholine, histamine and noradrenaline. Br J Pharmacol 1987; 90 (1) 147-150
• 36 White RM, Rivera CO, Davison CB. Differential contribution of endothelial function to vascular reactivity in conduit and resistance arteries from deoxycorticosterone-salt hypertensive rats. Hypertension 1996; 27 (6) 1245-1253
• 37 Kang KT. Endothelium-derived relaxing factors of small resistance arteries in hypertension. Toxicol Rev 2014; 30 (3) 141-148